This page is updated frequently with new Immune Diseases-related patent applications.
|Monomers and oligonucleotides comprising cycloaddition adduct(s)|
In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression..
|Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring|
Described herein are methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring based on the level of tigit, flg2 and/or il-33 expression and/or activity. In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of cancer and/or infections (e.g., chronic viral infection, intracellular and/or extracellular bacterial infection, and/or fungal infection).
The Brigham And Women's Hospital, Inc.
|Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases|
The present invention provides human anti-il-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to il-6 and that has an extended in vivo half-life for the treatment and prevention of il-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors..
The present invention provides antibodies and antigen-binding fragments thereof that bind specifically to blys, immunoglobulin chains thereof, variants thereof; and method of use thereof, e.g., for the treatment or prevention of inflammatory and/or immune diseases such as systemic lupus erythramatous; as well as polynucleotides encoding the immunoglobulin chains of such antibodies and fragments. Methods for the recombinant expression of immunoglobulin chains are also part of the present invention..
|Modulating gamma-c-cytokine activity|
Embodiments relate to peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
|Crystalline forms of a bruton's tyrosine kinase inhibitor|
Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
|Methods for treating or preventing neuroinflammation or autoimmune diseases|
Disclosed herein are ribonucleotide reductase inhibitors, compositions comprising ribonucleotide reductase inhibitors, and methods for treating and/or preventing autoimmune diseases and neuroinflammatory diseases with the ribonucleotide reductase inhibitors.. .
|Human antibodies to human tnf-like ligand 1a (tl1a)|
A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human tnf-like ligand 1a (htl1a) is provided. The human anti-htl1a antibodies are useful in treating diseases or disorders associated with tl1a, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation..
Regeneron Pharmaceuticals, Inc.
|Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases|
Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
Wherein each symbol is as described in the description, or a salt thereof has a superior pkc inhibitory action, and is useful as a prophylactic or therapeutic agent for immune diseases, inflammatory diseases and the like.. .
Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
The present invention relates to novel compounds having histone deacetylase 6 (hdac6) inhibitory activity, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (hdac6) inhibitory activity, and are effective for the prevention or treatment of hdac6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders..
Chong Kun Dang Pharmaceutical Corp.
Furo[3,4-b]pyran compounds and pharmaceutical uses
Furo[3,4-b]pyran compounds similar in chemical structure to the natural product known as tan-2483b and their use for treating cancer, osteoporosis, type 2 diabetes, or immune diseases.. .
Victoria Link Limited
Nucleic acid that inhibits expression of irf5
The present invention provides a nucleic acid having activity to suppress expression of irf5, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis and the like.. .
Kyowa Hakko Kirin Co., Ltd.
Fusion protein inhibiting taci-baff complex formation and preparation method therefor and use thereof
The present invention provides a fusion protein inhibiting taci-baff complex formation and preparation method therefor and use thereof. Specifically, the fusion protein of the present invention is of high biological activity for blocking baff/appril, and may significantly lower the serum igm concentration in normal balb/c mice as well as the serum igm and ige concentration in c57/b6 mice with asthma.
Shanghai Celgen Bio-pharmaceutical Co., Ltd.
The present invention is directed to novel retinoid-related orphan receptor gamma (rorγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by rorγ.. .
Glaxo Group Limited
Compositions and methods for modulating the immune system
A novel class of embryo derived peptides are described (preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a th2 type cytokine bias, in addition pif enhance endometrial receptivity by increasing adhesion molecules expression. Pif biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages.
Novel formulations of a bruton's tyrosine kinase inhibitor
Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Marker sequences for diagnosing and stratifying sle patients
The present invention relates to methods for identifying markers for systemic lupus erythematosus (sle) and to the markers identified with the aid of this method, which can differentiate between sle and other autoimmune diseases on the one hand and between different sle subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control in sle.
Sequencing-directed selection of tumor theranostics
The present disclosure relates to therapies for the treatment of tumor, autoimmune diseases, or other diseases. In some embodiments, the present disclosure can relate to subject-specific selection of humanized antibodies targeting clonal lineage specific marker proteins..
Method for identifying and validating dominant t helper cell epitopes using an hla-dm-assisted class ii binding assay
Rational design of immunotherapeutics relies on clear knowledge of the immunodominant epitopes of antigens. Current methods for identifying kinetically stable peptide-mhc complexes are in many cases inadequate for a number of reasons.
The Johns Hopkins University
Compositions of gm-csf and interleukin fusions for immune modulation and uses related thereto
This disclosure relates to recombinant proteins comprising a gm-csf sequence and an interleukin sequence and nucleic acids related thereto. In certain embodiments, the disclosure relates to recombinant proteins comprises n-terminal sequences that are the result of improved production techniques and uses for treating or preventing autoimmune diseases such as multiple sclerosis and cancer..
Children's Healthcare Of Atlanta, Inc.
Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen cd6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-monoclonal antibody for the diagnosis and treatment of autoimmune diseases, particularly the rheumatoid arthritis..
Centro De Inmunologia Molecular
Substituted amino triazoles useful as human chitinase inhibitors
Disclosed are amino triazole compounds substituted with a piperidinyl ring that is itself substituted with a heterocyclic ring. These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase.
Oncoarendi Therapeutics Sp. Z O.o.
Indole carboxamide compounds
Or a salt thereof, wherein: x is cr4 or n; r1, r2, r3, r4, and a are defined herein. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.
Composition for use in treating and/or preventing human condition, disorder or diseases
Composition comprising a metal and/or a semimetal, a sodium salt, a tranquilizer, a halogen, a carotenoid, grain, and a neutral gel for example for use in treating and/or preventing a condition, disorder or disease such as pain, metabolic diseases, fatigue, absence of appetite, cramps, immune diseases, inflammatory disease, cancer, neurological and/or psychiatric diseases.. .
Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways
Described herein are novel compositions comprising il-27 or nfil-3 modulators (i e , inhibitors or activators), and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, and modulating tim-3 activity or expression. These compositions, methods, and uses are useful for the treatment of chronic immune conditions, such as persistent infections, cancer, and autoimmune diseases..
The Brigham And Women's Hospital, Inc.
Macrocyclic therapeutic agents, methods of manufacture, and methods of treatment
The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.. .
University Of Florida Research Foundation, Incorporated
Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
Novel benzimidazoles according to formula i, able to inhibit jak are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or hypersecretion of interferons.. .
Immune Diseases topics:
Type 1 Diabetes
Follow us on Twitter
This listing is a sample listing of patent applications related to Immune Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.